IBA Dosimetry Advances Independent Machine QA at ASTRO

The new release of myQA® Machines enables more efficient radiation therapy machine quality assurance, integrated into the independent global QA platform myQA®

IBA Dosimetry Machine QA Screens Update


Chicago, USA, September 12, 2019 – IBA Dosimetry GmbH, a world-leading provider of radiation therapy integrated quality assurance (QA), announces the launch of the new enhanced myQA Machines 2019 software environment at the upcoming ASTRO congress.  

The latest version of the myQA Machines software enables significantly faster execution of all key Linac QA tests. It also allows machine QA tests to be performed independently of the Linac systems that are being verified.

The new myQA Machines has been designed to ensure QA efficiency through close integration with the treatment machines while maintaining independence from the machines to be tested, to provide the most reliable quality assurance performance.

To enhance workflow efficiency, each of the Linac specific tests of myQA Machines—like the MLC and VMAT checks, as well as the 2D and 3D imaging QA tests—can now be measured and analyzed easily in a single workflow that is integrated in one dedicated software interface. Test automation further contributes to QA efficiency and avoids human subjectivity during test analysis.

"With myQA, IBA Dosimetry has been the innovation leader for quality assurance platform solutions and has set the standard in making independent quality checks for radiation therapy cancer treatments safer and more efficient. We are excited to release the new myQA Machines, which is a testament to our commitment to the medical physics and radiation oncology community,” said Jean-Marc Bothy, President of IBA Dosimetry“We are very proud that today more than 1,500 healthcare centers worldwide trust myQA to independently QA their patient plans and treatment machines.”  



About myQA® Global QA Platform

With more than 1,500 customers worldwide, myQA is the leading global Quality Assurance platform. ThemyQAsoftware platform connects Quality Assurance applications, people, and know-how through a central database. It enables QA to be performed fully independent from the treatment machine technology and fully support its users by integrating the entire QA workflow. myQA provides access to all software application modules and data from one intuitive interface. Users also have a complete, instant overview of their results with the myQA Cockpit. myQA integrates all major tasks of the QA workflow, from beam scanning and machine QA, to imaging QA and patient QA. Furthermore, users can also integrate their individual hospital tests into myQA.

myQA connects colleagues and sites by providing access to common QA data and applications from one central software platform and one central database.

For more information visit https://www.iba-dosimetry.com/solutions/myqa/



About IBA Dosimetry

IBA Dosimetry GmbH innovates radiation therapy, proton therapy and diagnostic imaging through integrated Quality Assurance solutions that are efficient, intuitive and that provide peace of mind for healthcare professionals and patients around the world. The myQA® Global QA Platform is the backbone for Integrated Quality Assurance solutions. IBA Dosimetry has more than 220 international employees in four offices in Germany, France, China and USA. IBA Dosimetry is part of the IBA Group, a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer.

Find more information at: www.iba-dosimetry.com



Media Contact:

Ralf Schira
Director Global Marketing 
IBA Dosimetry